美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Renaissance International IPO ETF

22.20

-0.2902-1.29%

盤後：22.18-0.0248-0.11%16:10 EDT

成交量：1,125

成交額：2.50萬

市值：1,110.24萬

市盈率：- -

高：22.25

開：22.25

低：22.18

收：22.50

52周最高：26.25

52周最低：15.65

股本：50.00萬

流通股本：50.00萬

量比：0.57

換手率：0.22%

股息：0.14

股息率：0.65%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

*ST康佳A：主動終止上市事項待審議股票即將停牌

華納藥廠(688799.SH)子公司化學原料藥艾拉莫德獲批上市

華納藥廠：子公司艾拉莫德原料藥獲上市申請批准

恒瑞醫藥(600276.SH)子公司HRS-7535片上市許可申請獲受理

恒瑞醫藥：HRS-7535片藥品上市許可申請獲受理

新股消息 | FundPark：正計劃進行C輪融資有考慮上市但未有時間表

翰森製藥(03692.HK)：注射用HS-20093治療小細胞肺癌上市許可申請獲國家藥品監督管理局受理

翰森製藥(03692)：注射用HS-20093治療小細胞肺癌上市許可申請獲國家藥品監督管理局受理

瑞星股份被證監局責令定期報告 2023上市華西證券保薦

破發股翱捷科技跌3.18% 2022上市超募42億國泰海通保薦

從上市初期陣痛到業績反轉突圍，瑞晟智能的增長底層邏輯是什麼？

唯捷創芯跌5.24% 2022年上市募資26.7億中信建投保薦

吉華集團跌7.7% 2017年上市募資17.2億國投證券保薦

*ST卓然連虧1年半 A股共募13億IPO國投證券保薦

迪哲醫藥二度遞表港交所：上半年虧損超2億，「小眾靶點」天花板與現金流雙重壓力並存

管清友：很多科技股上市之初定價虛高，現有規則有明顯漏洞

凤凰网港股

管清友：很多科技股上市之初定價虛高，現有規則有明顯漏洞

凤凰网港股

香港高爾夫服務商高球品味(GLG.US)申請赴美IPO，擬籌資至多3000萬美元

西班牙遊戲運營商CIRSA股價漲幅擴大，目前累計上漲15.8%，正朝着上市以來最佳單日表現邁進。

消息人士：韓國外匯穩定基金購入了約200億美元的資金，這些資金是SK海力士在ADR上市後匯回的。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/IPOS/news?page=53"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IPOS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPOS\",,,,,undefined,":{"symbol":"IPOS","market":"US","secType":"STK","nameCN":"Renaissance International IPO ETF","latestPrice":22.2048,"timestamp":1789502400000,"preClose":22.495,"halted":0,"volume":1125,"hourTrading":{"tag":"盘后","latestPrice":22.18,"preClose":22.2048,"latestTime":"16:10 EDT","volume":6,"amount":133.2288,"timestamp":1789503007320,"change":-0.0248,"changeRate":-0.001117,"amplitude":0},"delay":0,"changeRate":-0.012900644587686251,"floatShares":500001,"shares":500001,"eps":0,"marketStatus":"已收盤","change":-0.2902,"latestTime":"09-15 16:00:00 EDT","open":22.25,"high":22.25,"low":22.18,"amount":24999,"amplitude":0.003112,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":22.495,"sharesOutstanding":400001,"nav":22.516307,"aum":11258175.95,"dividendRate":0.006485,"bidAskSpread":0.004932,"postHourTrading":{"tag":"盘后","latestPrice":22.18,"preClose":22.2048,"latestTime":"16:10 EDT","volume":6,"amount":133.2288,"timestamp":1789503007320,"change":-0.0248,"changeRate":-0.001117,"amplitude":0},"volumeRatio":0.565554,"impliedVol":0.9594,"impliedVolPercentile":0.996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPOS\",,,,,undefined,":{"symbol":"IPOS","floatShares":500001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.565554,"shares":500001,"dividePrice":0.144,"high":22.25,"amplitude":0.003112,"preClose":22.495,"low":22.18,"week52Low":15.65,"pbRate":"--","week52High":26.25,"institutionHeld":0,"latestPrice":22.2048,"eps":0,"divideRate":0.006485,"volume":1125,"delay":0,"ttmEps":0,"open":22.25,"prevYearClose":16.8936,"prevWeekClose":22.665,"prevMonthClose":23.3188,"prevQuarterClose":25.635,"fiveDayClose":23.3527,"twentyDayClose":23.895,"sixtyDayClose":25.6848},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IPOS\",params:#limit:5,,,undefined,":[{"date":"2026-09-11","symbol":"IPOS","amount":0.072205,"announcedDate":"2026-09-10","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-11","defaultRemindTime":1789133400000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-11","currency":"USD","dateTimestamp":1789099200000,"payDate":"2026-09-18"},{"date":"2026-06-12","symbol":"IPOS","amount":0.054103,"announcedDate":"2026-06-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-12","defaultRemindTime":1781271000000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-22","payableDate":"2026-06-12","currency":"USD","dateTimestamp":1781236800000,"payDate":"2026-06-22"},{"date":"2025-12-12","symbol":"IPOS","amount":0.017941,"announcedDate":"2025-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-12","defaultRemindTime":1765549800000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-12","currency":"USD","dateTimestamp":1765515600000,"payDate":"2025-12-19"},{"date":"2025-09-12","symbol":"IPOS","amount":0.007352,"announcedDate":"2025-09-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-12","defaultRemindTime":1757683800000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-12","currency":"USD","dateTimestamp":1757649600000,"payDate":"2025-09-19"},{"date":"2025-06-13","symbol":"IPOS","amount":0.13555,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-13","defaultRemindTime":1749821400000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-13","currency":"USD","dateTimestamp":1749787200000,"payDate":"2025-06-20"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IPOS\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-26","value":0.10823,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.15245,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-22","value":0.05857,"currency":"USD"},{"executeDate":"2018-03-16","recordDate":"2018-03-19","paymentDate":"2018-03-23","value":0.00775,"currency":"USD"},{"executeDate":"2018-06-15","recordDate":"2018-06-18","paymentDate":"2018-06-22","value":0.2024,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IPOS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IPOS\",pageSize:20,pageCount:53,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664972208","title":"*ST康佳A：主動終止上市事項待審議 股票即將停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2664972208","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664972208?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 17:09","pubTimestamp":1788340194,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897280","title":"華納藥廠(688799.SH)子公司化學原料藥艾拉莫德獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897280","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664897280?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 17:00","pubTimestamp":1788339652,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华纳药厂(688799.SH)发布公告，近日，公司全资子公司湖南华纳大药厂手性药物有限公司(简称“手性药物”)收到国家药品监督管理局签发的艾拉莫德《化学原料药上市申请批准通知书》(通知书编号：2026YS00837)，并在国家药品监督管理局药品审评中心(CDE)“原辅包登记信息”平台公示。艾拉莫德是艾拉莫德片的原料药。艾拉莫德片主要用于治疗活动性类风湿关节炎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490941.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","IPOS","688799"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897901","title":"華納藥廠：子公司艾拉莫德原料藥獲上市申請批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897901","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664897901?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 16:58","pubTimestamp":1788339520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897609","title":"恒瑞醫藥(600276.SH)子公司HRS-7535片上市許可申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897609","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664897609?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 16:47","pubTimestamp":1788338861,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司山东盛迪医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司HRS-7535片的药品上市许可申请获国家药监局受理。拟定适应症(或功能主治)：用于成人2型糖尿病患者的血糖控制。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","BK0028","LU1328615791.USD","BK0183","LU1997244956.HKD","LU0359201885.HKD","LU0405327494.USD","LU2328871848.SGD","LU0359202008.SGD","LU0359201612.USD","LU1255011170.USD","LU2289578879.USD","01276","IPOS","LU2495084118.USD","BK0012","BK0239","LU1580142542.USD","LU2488822045.USD","LU2097828805.USD","LU2580892789.USD","LU1064131003.USD","LU2097828474.EUR","LU2148510915.USD","LU2543165471.USD","BK0060","LU1146622755.USD","BK0188","LU2097828714.EUR","LU0405327148.USD","LU1997245094.SGD","600276","LU2580892862.HKD","LU1820825898.SGD","LU2097828557.USD","LU2097828631.EUR","LU1023057109.AUD","LU1781817850.SGD","LU1969619763.USD","LU1997245177.USD","BK1191","LU1655091616.SGD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897356","title":"恒瑞醫藥：HRS-7535片藥品上市許可申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897356","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664897356?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 16:40","pubTimestamp":1788338423,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664689767","title":"新股消息 | FundPark：正計劃進行C輪融資 有考慮上市 但未有時間表","url":"https://stock-news.laohu8.com/highlight/detail?id=2664689767","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664689767?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 16:35","pubTimestamp":1788338145,"startTime":"0","endTime":"0","summary":"另外，FundPark 联合创办人及中国区总裁莫招杰称，该公司较早前已完成B轮融资，正计划进行C轮融资。他又称，随着公司业务进一步发展，确有考虑上市计划，但现时未有时间表。孙慧来称，FundPark已支持逾4万家中小企，通过 AI 驱动的动态融资、前瞻性洞察以及增长支援服务，协助企业应对跨境贸易挑战，累计支用贷款总额超过90亿美元。他表示，FundPark 现时有逾200名员工、当中约100人在深圳办公室，主要从事技术层面的工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490912.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664892083","title":"翰森製藥(03692.HK)：注射用HS-20093治療小細胞肺癌上市許可申請獲國家藥品監督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664892083","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664892083?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 16:32","pubTimestamp":1788337920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664067892","title":"翰森製藥(03692)：注射用HS-20093治療小細胞肺癌上市許可申請獲國家藥品監督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664067892","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664067892?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 16:32","pubTimestamp":1788337920,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，于2026年9月2日，集团创新药注射用HS-20093上市许可申请获中国国家药品监督管理局(NMPA)受理，用于治疗既往含铂治疗失败的小细胞肺癌(SCLC)成人患者。注射用HS-20093是一款集团自主研发的B7-H3靶向抗体-药物偶联物(ADC)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1191","IPOS","03692","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897844","title":"瑞星股份被證監局責令定期報告 2023上市華西證券保薦","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897844","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664897844?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 16:28","pubTimestamp":1788337682,"startTime":"0","endTime":"0","summary":"中国经济网北京9月2日讯 中国证监会网站昨日发布河北证监局关于对河北瑞星燃气设备股份有限公司及谷红军、谷红民、孙铁军、王俊生采取责令定期报告行政监管措施的决定。2026年一季度未召开审计委员会会议。　　瑞星股份2023年7月3日在北交所上市，发行数量为28,680,000股；32,982,000股，发行价格为5.07元/股，保荐人、承销商为华西证券股份有限公司，签字保荐代表人为周曼、廖高迁。　　瑞星股份发行费用总额为24,972,679.32元；26,805,626.37元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260902/32357807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002926","BK0276","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897304","title":"破發股翱捷科技跌3.18% 2022上市超募42億國泰海通保薦","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897304","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664897304?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 16:19","pubTimestamp":1788337141,"startTime":"0","endTime":"0","summary":"中国经济网北京9月2日讯 翱捷科技 今日收报94.69元，跌幅3.18%。该股目前处于破发状态。　　翱捷科技于2022年1月14日在上交所科创板上市，发行的股票数量为4183.0089万股，发行价格为164.54元/股，保荐人为海通证券股份有限公司，保荐代表人为王鹏程、龚思琪。翱捷科技最终募集资金净额比原计划多41.66亿元。　　翱捷科技首次公开发行股票的发行费用总额为3.37亿元，其中，保荐及承销费用3.10亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260902/32357797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0012","BK1147","BK0184","91545","02611","BK0276","BK1564","BK0028","BK0183","IPOS","BK0188","BK0201","601211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664921828","title":"從上市初期陣痛到業績反轉突圍，瑞晟智能的增長底層邏輯是什麼？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664921828","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664921828?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 16:10","pubTimestamp":1788336602,"startTime":"0","endTime":"0","summary":"A股上市公司2026上半年业绩已披露完成。细究原因，并非是瑞晟智能的经营出现重大漏洞，疫情、研发加大、诉讼赔款等是主要原因。此外，因疫情管控需要，人员流动受到限制，特别是出入境受到管制，对瑞晟智能项目的实施及订单的签订影响严重。在之后的两年中，尽管瑞晟智能净利润仍在下滑，但扣非净利润仍保持增长态势。2026上半年，瑞晟智能营业收入较上年增长 50.84%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/02/20260902959599.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/02/20260902959599.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260902/32357791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","688215","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664929998","title":"唯捷創芯跌5.24% 2022年上市募資26.7億中信建投保薦","url":"https://stock-news.laohu8.com/highlight/detail?id=2664929998","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664929998?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 16:09","pubTimestamp":1788336542,"startTime":"0","endTime":"0","summary":"中国经济网北京9月2日讯 唯捷创芯 今日收报26.4元，跌幅5.24%。　　唯捷创芯于2022年4月12日在上交所科创板上市，公开发行股票4008.00万股，发行价格为66.60元/股，保荐机构为中信建投证券股份有限公司，保荐代表人为武鑫、沈杰。　　唯捷创芯首次公开发行股票募集资金总额为266,932.80万元，扣除发行费用后，募集资金净额为250,251.13万元。　　唯捷创芯首次公开发行股票的发行费用总额16,681.67万元，其中，保荐及承销费用14,731.30万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260902/32357783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["601066","688153","BK0214","BK0276","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664892996","title":"吉華集團跌7.7% 2017年上市募資17.2億國投證券保薦","url":"https://stock-news.laohu8.com/highlight/detail?id=2664892996","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664892996?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 16:09","pubTimestamp":1788336542,"startTime":"0","endTime":"0","summary":"中国经济网北京9月2日讯 吉华集团 今日收报7.31元，跌幅7.7%。目前该股处于破发状态。　　吉华集团于2017年6月15日在上交所主板上市，发行数量为10,000万股，发行价格为17.20元/股，保荐机构为安信证券股份有限公司，保荐代表人为袁弢、湛瑞锋。　　吉华集团发行费用总额为8,751.76万元，其中承销保荐费7,795.57万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260902/32357784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["603980","BK0229","IPOS","161027","BK0192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664892581","title":"*ST卓然連虧1年半 A股共募13億IPO國投證券保薦","url":"https://stock-news.laohu8.com/highlight/detail?id=2664892581","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664892581?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 15:56","pubTimestamp":1788335761,"startTime":"0","endTime":"0","summary":"中国经济网北京9月2日讯 上海卓然工程技术股份有限公司 近日披露2026年半年度报告。报告期内，公司实现营业收入3.45亿元，同比减少64.32%；归属于上市公司股东的净利润-9861.10万元，上年同期为-21.90万元；归属于上市公司股东的扣除非经常性损益的净利润-1.35亿元，上年同期为170.64万元；经营活动产生的现金流量净额1.68亿元，上年同期为-2.59亿元。　　卓然股份于2023年向特定对象发行股票募集资金。　　经计算，卓然股份两次累计募资13.33亿元。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/02/20260902365365.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/02/20260902365365.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260902/32357771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["399300","KCE","03188","161027","159982","688121","BK0251","07233","FRHC","BK1147","IPOS","83130","REDS","82846","02827","BK4127","03130","02846","83188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664894762","title":"迪哲醫藥二度遞表港交所：上半年虧損超2億，「小眾靶點」天花板與現金流雙重壓力並存","url":"https://stock-news.laohu8.com/highlight/detail?id=2664894762","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664894762?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 15:46","pubTimestamp":1788335190,"startTime":"0","endTime":"0","summary":"目前，迪哲医药两款核心产品舒沃哲和高瑞哲均已进入国家医保目录。截至2026年中，迪哲医药无控股股东和实际控制人。就在9月1日，迪哲医药发布公告称，公司与阿斯利康签署《许可协议》，授予阿斯利康在全球范围内独家开发、商业化舒沃哲的权利。不过，市场依然对两款产品的天花板存在争议。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788335043232116627","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4585","BK1515","BK4588","IPOS","09939","BK1574","SPHQ","159399","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664892368","title":"管清友：很多科技股上市之初定價虛高，現有規則有明顯漏洞","url":"https://stock-news.laohu8.com/highlight/detail?id=2664892368","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664892368?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 15:30","pubTimestamp":1788334203,"startTime":"0","endTime":"0","summary":"管清友指出，很多科技股上市之初的价格其实是虚高的。“我们现有的规则明显是有漏洞的。”管清友举例说，很多股票上市时流通盘很小，机构用很少的资金就能把价格拉高，等纳入指数之后，被动基金被动接盘。管清友呼吁，新股上市定价虚高、前几个交易日价格虚高、后续出现抛物线式下跌，这个问题解决起来比很多复杂机制问题要容易得多，关键在于有没有决心去改。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://original.ifeng.com/c/8w5m6CIczFQ","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02834","TTTN","03086","09834","BK1147","XLK","07522","BK4585","09086","BK4588","07261","07568","VGT","07266","IPOS","03034","03455"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664274894","title":"管清友：很多科技股上市之初定價虛高，現有規則有明顯漏洞","url":"https://stock-news.laohu8.com/highlight/detail?id=2664274894","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664274894?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 15:30","pubTimestamp":1788334203,"startTime":"0","endTime":"0","summary":"管清友指出，很多科技股上市之初的价格其实是虚高的。“我们现有的规则明显是有漏洞的。”管清友举例说，很多股票上市时流通盘很小，机构用很少的资金就能把价格拉高，等纳入指数之后，被动基金被动接盘。管清友呼吁，新股上市定价虚高、前几个交易日价格虚高、后续出现抛物线式下跌，这个问题解决起来比很多复杂机制问题要容易得多，关键在于有没有决心去改。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8w5m6CIczFQ","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IPOS","09834","BK1147","03034","BK4588","TTTN","07266","07568","02834","03086","07522","VGT","07261","XLK","03455","09086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664894573","title":"香港高爾夫服務商高球品味(GLG.US)申請赴美IPO，擬籌資至多3000萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664894573","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664894573?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 15:26","pubTimestamp":1788333986,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FRHC","KCE","IPOS","REDS","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664948698","title":"西班牙遊戲運營商CIRSA股價漲幅擴大，目前累計上漲15.8%，正朝着上市以來最佳單日表現邁進。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664948698","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664948698?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 15:26","pubTimestamp":1788333982,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664891941","title":"消息人士：韓國外匯穩定基金購入了約200億美元的資金，這些資金是SK海力士在ADR上市後匯回的。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664891941","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664891941?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 15:09","pubTimestamp":1788332982,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["SKHN","SKHZ","SKHA","SKHL","EDZ","SKHY","BK4141","DRAL","SK","07709","SKHYV","CVY","EEMO","HYNX","SAPH","RAMZ","IPOS","LU0823413587.USD","LU0823397285.USD","APIE","SKDD","SKHU","DIVL","RAM","SKHX","SKUU","LU1956131251.USD","ARMH","DINT","LU0823413660.USD","AADR","LU0823397103.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":55,"pageCount":53,"totalSize":1095,"code":"91000000","status":"200"}]}}